CXCL13 and rheumatoid arthritis: Filgotinib has also been shown to reduce cytokine expression that may affect B cells indirectly (CXCL13, IL‐7, IL‐21) in RA patients, and the treatment was associated with a slight increase in peripheral B cell numbers [36].